Advances in Hormone Replacement Therapy for Adult Adrenal Insufficiency

CHEN Xiaoxue; LI Ran; ZHU Huijuan; LU Lin

doi:10.12376/j.issn.2097-0501.2023.03.016

Journal of Rare Diseases > 2023 > 2(3): 436-441. > DOI: 10.12376/j.issn.2097-0501.2023.03.016

CHEN Xiaoxue, LI Ran, ZHU Huijuan, LU Lin. Advances in Hormone Replacement Therapy for Adult Adrenal Insufficiency[J]. Journal of Rare Diseases, 2023, 2(3): 436-441. DOI: 10.12376/j.issn.2097-0501.2023.03.016

Citation:

PDF (1103 KB)

Advances in Hormone Replacement Therapy for Adult Adrenal Insufficiency

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences 2021-I2M-C&T-B-001

More Information

Corresponding author:
LU Lin, E-mail: lulin88@sina.com
Received Date: June 16, 2023
Accepted Date: September 25, 2023
Available Online: September 08, 2023

Graphical Abstract

Abstract

Abstract

Adrenal insufficiency is a disease characterized by insufficient secretion of adrenocortical hormones, usually treated with glucocorticoid replacement therapy. The routine drugs have two forms-short-acting and long-acting. The shorter one should be taken 2-3 times a day resulting hormone level of patients fluctuating greatly within a day. Although long-acting drugs reduce the frequency of administration, it is easy to lead to excessive replacement, resulting in adverse effects on metabolism. New alternative treatments for adult patients have emerged, including modified-release hydrocortisone and hydrocortisone subcutaneous infusion pumps. In this review, we briefly introduce these new therapies, emphasizing the pharmacodynamics and pharmacokinetics of the replacement, the effects on metabolism and drug safety, aiming at contributing to the future clinical practice.
- adrenal insufficiency,
- adult,
- glucocorticoid,
- modified-release hydrocortisone,
- subcutaneous infusion pump

FullText(HTML)

References (30)

References

[1]	Hahner S, Ross RJ, Arlt W, et al. Adrenal insufficiency[J]. Nat Rev Dis Primers, 2021, 7(1): 19. doi: 10.1038/s41572-021-00252-7
[2]	Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis[J]. N Engl J Med, 2019, 381(9): 852-861. doi: 10.1056/NEJMra1807486
[3]	Nowotny H, Ahmed SF, Bensing S, et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis[J]. Endocrine, 2021, 71(3): 586-594. doi: 10.1007/s12020-021-02649-6
[4]	Auer MK, Paizoni L, Hofbauer LC, et al. Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency[J]. J Steroid Biochem Mol Biol, 2020, 204: 105734. doi: 10.1016/j.jsbmb.2020.105734
[5]	Quinkler M, Ekman B, Marelli C, et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency[J]. Endocr Connect, 2017, 6(1): 1-8. doi: 10.1530/EC-16-0081
[6]	Husebye ES, Pearce SH, Krone NP, et al. Adrenal insufficiency[J]. Lancet, 2021, 397(10274): 613-629. doi: 10.1016/S0140-6736(21)00136-7
[7]	Buning JW, Touw DJ, Brummelman P, et al. Pharmacokinetics of oral hydrocortisone-results and implications from a randomized controlled trial[J]. Metabolism, 2017, 71: 7-16. doi: 10.1016/j.metabol.2017.02.005
[8]	Johannsson G, Bergthorsdottir R, Nilsson AG, et al. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study[J]. Eur J Endocrinol, 2009, 161(1): 119-130. doi: 10.1530/EJE-09-0170
[9]	Whitaker M, Debono M, Huatan H, et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure[J]. Clin Endocrinol (Oxf), 2014, 80(4): 554-561. doi: 10.1111/cen.12316
[10]	Bannon CAM, Border D, Hanson P, et al. Early metabolic benefits of switching hydrocortisone to modified release hydrocortisone in adult adrenal insufficiency[J]. Front Endocrinol (Lausanne), 2021, 12: 641247. doi: 10.3389/fendo.2021.641247
[11]	Gasco V, Giannelli J, Campioni L, et al. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency[J]. J Endocrinol Invest, 2023, 46(3): 587-597.
[12]	Dineen R, Martin-Grace J, Ahmed KMS, et al. Cardiometabolic and psychological effects of dual-release hydrocorti-sone: a cross-over study[J]. Eur J Endocrinol, 2021, 184(2): 253-265. doi: 10.1530/EJE-20-0642
[13]	Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment[J]. Nat Rev Endocrinol, 2020, 16(8): 437-447. doi: 10.1038/s41574-020-0341-0
[14]	Frara S, Chiloiro S, Porcelli T, et al. Bone safety of dual-release hydrocortisone in patients with hypopituitarism[J]. Endocrine, 2018, 60(3): 528-531. doi: 10.1007/s12020-017-1512-1
[15]	Guarnotta V, Di Stefano C, Giordano C. Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency[J]. Sci Rep, 2022, 12(1): 13280. doi: 10.1038/s41598-022-13506-5
[16]	Espiard S, McQueen J, Sherlock M, et al. Improved urinary cortisol metabolome in addison disease: a prospective trial of dual-release hydrocortisone[J]. J Clin Endocrinol Metab, 2021, 106(3): 814-825. doi: 10.1210/clinem/dgaa862
[17]	Boesen VB, Borresen SW, Christoffersen T, et al. The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments[J]. Endocrine, 2021, 71(2): 467-475. doi: 10.1007/s12020-020-02507-x
[18]	Nilsson AG, Marelli C, Fitts D, et al. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency[J]. Eur J Endocrinol, 2014, 171(3): 369-377. doi: 10.1530/EJE-14-0327
[19]	Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease[J]. Eur J Endocrinol, 2007, 157(1): 109-112. doi: 10.1530/EJE-07-0052
[20]	Zhang L, Cai K, Wang Y, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men[J]. Am J Mens Health, 2019, 13(1): 1557988318818280.
[21]	Puig-Domingo M, Díaz G, Nicolau J, et al. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide[J]. Eur J Endocrinol, 2008, 159(5): 653-657. doi: 10.1530/EJE-08-0269
[22]	Merza Z, Rostami-Hodjegan A, Memmott A, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia[J]. Clin Endocrinol (Oxf), 2006, 65(1): 45-50. doi: 10.1111/j.1365-2265.2006.02544.x
[23]	Melikyan MA, Gubaeva DN, Kareva MA. Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism[J]. Probl Endokrinol (Mosk), 2020, 66(3): 81-87. doi: 10.14341/probl12421
[24]	Gagliardi L, Nenke MA, Thynne TR, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial[J]. J Clin Endocrinol Metab, 2014, 99(11): 4149-4157. doi: 10.1210/jc.2014-2433
[25]	Oksnes M, Björnsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial[J]. J Clin Endocrinol Metab, 2014, 99(5): 1665-1674. doi: 10.1210/jc.2013-4253
[26]	Cardini F, Torlone E, Bini V, et al. Continuous subcu-taneous hydrocortisone infusion in a woman with secondary adrenal insufficiency[J]. Endocrine, 2019, 63(2): 398-400. doi: 10.1007/s12020-018-1780-4
[27]	Kalafatakis K, Russell GM, Harmer CJ, et al. Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man[J]. Proc Natl Acad Sci USA, 2018, 115(17): E4091-E4100.
[28]	Violaris IG, Kalafatakis K, Zavala E, et al. Modelling hydrocortisone pharmacokinetics on a subcutaneous pulsatile infusion replacement strategy in patients with adrenocortical insufficiency[J]. Pharmaceutics, 2021, 13(6): 769. doi: 10.3390/pharmaceutics13060769
[29]	Björnsdottir S, Øksnes M, Isaksson M, et al. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy[J]. Clin Endocrinol (Oxf), 2015, 83(1): 28-35. doi: 10.1111/cen.12670
[30]	Khanna A, Khurana R, Kyriacou A, et al. Management of adrenocortical insufficiency with continuous subcutaneous hydrocortisone infusion: long-term experience in three patients[J]. Endocrinol Diabetes Metab Case Rep, 2015, 2015: 150005.

[1]	XIE Shiyao, LIU Ziyu, LI Shunping. Present Situation and Countermeasures of China′s Legal Responses to Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(3): 405-410. DOI: 10.12376/j.issn.2097-0501.2024.03.021
[2]	DONG Xinran, ZHOU Wenhao. Work Plan for the Clinical Utility & Usefulness Measures Working Group of Medical Genome Committee[J]. Journal of Rare Diseases, 2024, 3(3): 304-309. DOI: 10.12376/j.issn.2097-0501.2024.03.005
[3]	DONG Xinran, ZHOU Wenhao. The China Neonatal Genomes Project(CNGP): New Advances in the Cohort Study of Genotype and Phenotype of Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(3): 280-287. DOI: 10.12376/j.issn.2097-0501.2024.03.002
[4]	LI Kexin, CHEN Jingdan, ZHANG Dingding, GUO Wudong, ZHENG Jiayin, LI Linkang, ZHAO Kun, ZHANG Shuyang. Thoughts on Selection of Rare Diseases and Prioritized Research Topics[J]. Journal of Rare Diseases, 2024, 3(2): 269-274. DOI: 10.12376/j.issn.2097-0501.2024.02.018
[5]	WANG Shaohong, LIU Xin, LIU Qingyang, TANG Yan, ZHANG Bo. Overview and Analysis of Rare Disease Drugs Approved for Market in China, the United States, the European Union, and Japan in 2023[J]. Journal of Rare Diseases, 2024, 3(2): 202-213. DOI: 10.12376/j.issn.2097-0501.2024.02.008
[6]	LIU Qingyang, LIU Xin, ZUO Wei, WANG Shaohong, ZHANG Bo, ZHANG Shuyang. Study on Drug List and Accessibility of Rare Diseases Based on the China′s Second List of Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(2): 195-201. DOI: 10.12376/j.issn.2097-0501.2024.02.007
[7]	LI Kexin, ZHAO Kun, ZHENG Jiayin, YANG Yuqi, LI Linkang. Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases[J]. Journal of Rare Diseases, 2023, 2(4): 596-601. DOI: 10.12376/j.issn.2097-0501.2023.04.015
[8]	ZHANG Xueyi, SUN Bo, CHEN Guilin, HU Ge, LI Qing, QIU Guixing. Computer Vision in Medical Imaging and its Impact on the Rare Musculoskeletal Diseases[J]. Journal of Rare Diseases, 2023, 2(4): 589-595. DOI: 10.12376/j.issn.2097-0501.2023.04.014
[9]	TAO Libo, WANG Fangxu, JIA Fanghong, YANG Yulin, ZHENG Jiayin, ZHANG Shuyang. The Exploration and Analysis of Constructing a Multiple Health Security System for Rare Diseases in China[J]. Journal of Rare Diseases, 2023, 2(1): 135-142. DOI: 10.12376/j.issn.2097-0501.2023.01.019
[10]	ZHANG Haiqin, LI Shunping, FENG Junchao. Application Status, Problems and Suggestions of Commerical Health Insurance in Medical Security for Rare Dsieases in China[J]. Journal of Rare Diseases, 2022, 1(1): 84-88. DOI: 10.12376/j.issn.2097-0501.2022.01.014

Cited By

Get Citation

PDF

XML

Article views (245) PDF downloads (51)

Turn off MathJax

Article Contents

Abstract

References

Advances in Hormone Replacement Therapy for Adult Adrenal Insufficiency

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content